Burnet Institute
14
4
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.1%
1 terminated/withdrawn out of 14 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)
Role: collaborator
Characterizing Humoral Immune Response to Mosquito Bites
Role: collaborator
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
Role: collaborator
Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons
Role: collaborator
Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB
Role: collaborator
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Role: collaborator
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
Role: collaborator
COVID-19 Transmission and Morbidity in Malawi
Role: collaborator
Tools for the Integrated Management of Childhood Illness: Cross-country Quasi-experimental Pre-post Study in Kenya and Senegal
Role: collaborator
Reaching mEthadone Users Attending Community pHarmacies With HCV
Role: collaborator
Eliminate Hepatitis C/EC Partnership Evaluation Protocol
Role: collaborator
Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test
Role: collaborator
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Role: collaborator
Comparative Evaluation of PUSPENs and C&Cs
Role: collaborator
All 14 trials loaded